Knowledge Center

Article / Jul 27, 2015

Hovione and Invion sign development agreement for first inhaled non-steroidal anti-inflammatory for asthma

Authors:
Source:
Manufacturing Chemist, 27 July 2015

Portuguese API manufacturer Hovione has agreed with Invion to progress the development of inhaled INV104 (zafirlukast) as a potential new treatment for asthma.

Hovione and the Australian drug developer will collaborate to develop the proprietary novel technology – a dry powder formulation of the compound INV104 (zafirlukast) delivered by Hovione’s inhaler.

Related links

Read article here

Also in the Knowledge Center

Related Content

Particle Engineering for Inhalation and Nasal

Hovione is a global expert and recognized leader in particle engineering, an essential technology when developing inhalation drug products.

Page
Read more

High value applications

Hovione provides off-patent APIs that can be used with confidence where the choice of active ingredient is critical.

Page
Read more

HPAPI – Highly Potent API

Our service for HPAPIs ranges from Drug Substance to Particle Engineering.

Page
Read more